Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Hulse

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Psychiatry and Clinical Neurosciences|February 1, 2005
Acculturation and eating disorders in Asian and Caucasian Australian adolescent girlsPiangchai S Jennings, David Forbes, Brett McDermott, et al.
Journal of Clinical Medicine|October 14, 2022
Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?Alexander Gallo, Tim MacDonald, Kellie Bennett, et al.
Journal of Psychopharmacology (Oxford, England)|May 19, 2012
Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case seriesGary Hulse, George O'Neil, Noella Morris, et al.
Current Drug Abuse Reviews|January 28, 2012
The efficacy of stepped care models involving psychosocial treatment of alcohol use disorders and nicotine dependence: a systematic review of the literatureAndreas Jaehne, Barbara Loessl, Katrin Frick, et al.
Addiction (Abingdon, England)|August 29, 2018
Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, AustraliaErin Kelty, Duong Tran, Tina Lavin, et al.
Current Pharmaceutical Design|June 20, 2015
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous SystemGary Hulse, Erin Kelty, Sean Hood, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implantsGary P Jeffrey, Gerry MacQuillan, Fern Chua, et al.
Neuroimage|February 2, 2011
24-month effect of smoking cessation on cognitive function and brain structure in later lifeOsvaldo P Almeida, Griselda J Garrido, Helman Alfonso, et al.
Journal of Psychopharmacology (Oxford, England)|June 7, 2014
Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol useErin Kelty, Lesleigh Hayes, Graeme O'Neil, et al.
Annals of General Psychiatry|June 9, 2018
The frequency of <i>DRD2</i> rs1076560 and <i>OPRM1</i> rs1799971 in substance use disorder patients from the United Arab EmiratesHiba Alblooshi, Gary Hulse, Wael Osman, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Psychiatry and Clinical Neurosciences|February 1, 2005
Acculturation and eating disorders in Asian and Caucasian Australian adolescent girlsPiangchai S Jennings, David Forbes, Brett McDermott, et al.
Journal of Clinical Medicine|October 14, 2022
Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?Alexander Gallo, Tim MacDonald, Kellie Bennett, et al.
Journal of Psychopharmacology (Oxford, England)|May 19, 2012
Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case seriesGary Hulse, George O'Neil, Noella Morris, et al.
Current Drug Abuse Reviews|January 28, 2012
The efficacy of stepped care models involving psychosocial treatment of alcohol use disorders and nicotine dependence: a systematic review of the literatureAndreas Jaehne, Barbara Loessl, Katrin Frick, et al.
Addiction (Abingdon, England)|August 29, 2018
Prevalence and safety of acamprosate use in pregnant alcohol-dependent women in New South Wales, AustraliaErin Kelty, Duong Tran, Tina Lavin, et al.
Current Pharmaceutical Design|June 20, 2015
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous SystemGary Hulse, Erin Kelty, Sean Hood, et al.
Hepatology (Baltimore, Md.)|December 26, 2006
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implantsGary P Jeffrey, Gerry MacQuillan, Fern Chua, et al.
Neuroimage|February 2, 2011
24-month effect of smoking cessation on cognitive function and brain structure in later lifeOsvaldo P Almeida, Griselda J Garrido, Helman Alfonso, et al.
Journal of Psychopharmacology (Oxford, England)|June 7, 2014
Changes in hospital and out-patient events and costs following implant naltrexone treatment for problematic alcohol useErin Kelty, Lesleigh Hayes, Graeme O'Neil, et al.
Annals of General Psychiatry|June 9, 2018
The frequency of <i>DRD2</i> rs1076560 and <i>OPRM1</i> rs1799971 in substance use disorder patients from the United Arab EmiratesHiba Alblooshi, Gary Hulse, Wael Osman, et al.
Pageof 5